Библиографические ссылки
1. Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
2. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71: 209–249.
3. Buys S.S., Partridge E., Black A., et al. Effect of screening on ovarian cancer mortality: the PLCO trial. JAMA. 2011;305(22):2295–2303.
4. Kurman R.J., Shih I M. The Dualistic Model of ovarian carcinogenesis revisited. Am J Pathol. 2016;186(4):733–747.
5. ACOG Committee Opinion No. 774. Opportunistic Salpingectomy for Ovarian Cancer Prevention. Obstet Gynecol. 2019;133:e279–e284.
6. Kuchenbaecker K.B., Hopper J.L., Barnes D.R., et al. Risks for BRCA1/2 carriers. JAMA. 2017; 317(23):2402–2416.
7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Oral contraceptives and ovarian cancer. Lancet. 2008;371:303–314.
8. Pearce C.L., Templeman C., Rossing M.A., et al. Endometriosis and ovarian cancer risk by histotype. Lancet Oncol. 2012;13(4):385–394.
9. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial ovarian cancer. Lancet. 2019;393:1240–1253.
10. du Bois A., Reuss A., Pujade Lauraine E., et al. Surgical outcome and prognosis in advanced ovarian cancer. Cancer. 2009;115:1234–1244.
11. Moore K., Colombo N., Scambia G., et al. Olaparib maintenance in newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–2505.
12. Menon U., Gentry Maharaj A., Burnell M., et al. UKCTOCS long term mortality results. Lancet. 2021;397:2182–2193.
13. Ahmad O.B., Boschi Pinto C., Lopez A.D., et al. Age Standardization of Rates: WHO Standard. GPE Discussion Paper No.31. Geneva: WHO; 2001.
14. Torre L.A., Trabert B., DeSantis C.E., et al. Ovarian cancer statistics. CA Cancer J Clin. 2018;68: 284–296.
15. Colombo N., Sessa C., du Bois A., et al. ESMO–ESGO consensus conference on ovarian can-cer. Ann Oncol. 2019;30:672–705.
